Corin was granted approval under the CE Mark for its Apollo robotic-assisted surgical platform and the ApolloKnee software application.
Enhancements of the new platform include objective pre-resection balance of the knee, autonomous planning tailored to individual surgeon preferences, a gesture-controlled workflow, robotic-assisted tibial cutting, seamless integration with the CorinConnect surgeon portal and the ability to support multiple surgical applications.
The CE approval allows Corin to commercialize Apollo and the ApolloKnee procedure across the European Union, broadening the availability of this technology since its FDA 510(k) clearance announcement in November 2023.
Jon Serbousek, CEO of Corin Group and Senior Advisor to parent company Permira, commented on the milestone, “Attaining CE approval for Apollo is a testament to Corin’s commitment to innovation and excellence, in Europe and around the world. This approval will enable us to bring our advanced balancing technology to more facilities, transforming the way joint replacements are performed.”
“ApolloKnee represents a significant leap forward in Total Knee Arthroplasty (TKA). The pre-resection BalanceBot provides an objective, robotic knee balance through the entire range of motion before the surgeon commits to making any bone cuts. This approach gives surgeons the freedom to use any alignment philosophy with a tibia-first or femur-first workflow,” said Dr Jim Pierrepont, Global Franchise Lead at Corin Group.
Corin was granted approval under the CE Mark for its Apollo robotic-assisted surgical platform and the ApolloKnee software application.
Enhancements of the new platform include objective pre-resection balance of the knee, autonomous planning tailored to individual surgeon preferences, a gesture-controlled workflow, robotic-assisted tibial...
Corin was granted approval under the CE Mark for its Apollo robotic-assisted surgical platform and the ApolloKnee software application.
Enhancements of the new platform include objective pre-resection balance of the knee, autonomous planning tailored to individual surgeon preferences, a gesture-controlled workflow, robotic-assisted tibial cutting, seamless integration with the CorinConnect surgeon portal and the ability to support multiple surgical applications.
The CE approval allows Corin to commercialize Apollo and the ApolloKnee procedure across the European Union, broadening the availability of this technology since its FDA 510(k) clearance announcement in November 2023.
Jon Serbousek, CEO of Corin Group and Senior Advisor to parent company Permira, commented on the milestone, “Attaining CE approval for Apollo is a testament to Corin’s commitment to innovation and excellence, in Europe and around the world. This approval will enable us to bring our advanced balancing technology to more facilities, transforming the way joint replacements are performed.”
“ApolloKnee represents a significant leap forward in Total Knee Arthroplasty (TKA). The pre-resection BalanceBot provides an objective, robotic knee balance through the entire range of motion before the surgeon commits to making any bone cuts. This approach gives surgeons the freedom to use any alignment philosophy with a tibia-first or femur-first workflow,” said Dr Jim Pierrepont, Global Franchise Lead at Corin Group.
Copy to clipboard 
